

CITATION REPORT

List of articles citing

Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis

DOI: 10.1186/s12933-017-0575-x
Cardiovascular Diabetology, 2017, 16, 93.

Source: <https://exaly.com/paper-pdf/68485989/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Hospitalisation risk for HF: antidiabetic classes compared. <i>Reactions Weekly</i> , 2017 , 1669, 8-8	0	
28	Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. <i>JACC: Heart Failure</i> , 2018 , 6, 445-451	7.9	42
27	Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 91	8.7	31
26	Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. <i>Cardiovascular Diabetology</i> , 2018 , 17, 101	8.7	77
25	Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018 , 17, 73	8.7	83
24	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2018 , 17, 102	8.7	14
23	The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. <i>Diabetes Therapy</i> , 2019 , 10, 1771-1792	3.6	27
22	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2019 , 18, 79	8.7	16
21	Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019 , 13, 1893-1896	8.9	
20	Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents. <i>Journal of Medical Economics</i> , 2020 , 23, 401-406	2.4	2
19	Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. <i>Cardiovascular Diabetology</i> , 2020 , 19, 17	8.7	19
18	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 604-617 ^{12,3}	12.3	22
17	Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 682-691	6.7	12
16	Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 991-1028	3.6	8
15	The effect of sodium-glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies. <i>Diabetic Medicine</i> , 2021 , 38, e14600	3.5	0
14	Association between cortisol and left ventricular diastolic dysfunction in patients with diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2021 ,	3.9	0
13	Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. <i>Diabetes Research and Clinical Practice</i> , 2021 , 179, 109024	7.4	1

12	Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2021 , 47, 101275	5.4	1
11	Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2021 , 20, 213	8.7	5
10	Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis. <i>Diabetes Therapy</i> , 2021 , 13, 25	3.6	1
9	Incident heart failure and myocardial infarction in sodium-glucose cotransporter 2 versus dipeptidyl peptidase-4 inhibitor users.		
8	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.. <i>Circulation</i> , 2022 , CIR0000000000001040	16.7	15
7	Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.. <i>ESC Heart Failure</i> , 2022 ,	3.7	2
6	Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis.. <i>Endocrine Journal</i> , 2022 ,	2.9	
5	Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. <i>Journal of Diabetes and Metabolic Disorders</i> ,	2.5	
4	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. <i>Advances in Therapy</i> , 2021 , 39, 845	4.1	2
3	Defining explicit definitions of potentially inappropriate prescriptions for antidiabetic drugs in patients with type 2 diabetes: A systematic review. 2022 , 17, e0274256		0
2	Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. 2023 , 49, 101419		0
1	Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes. 2023 , 10, 100135		0